Biogen Inc. announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study. 

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakne...

Cencora to invest $1bn in US pharma distribution network

Celltrion Signs Licensing Deal with U.S. Kaigene for Two Antibody Drug Candidates